Coherus to Acquire Surface Oncology

–Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiplenext-generationimmunotherapies in clinical development funded bygrowing revenues –

Related Keywords

United States ,Canada ,China ,Cambridge ,Cambridgeshire ,United Kingdom ,Rob Ross ,Junshi Biosciences ,Denny Lanfear ,Coherus Biosciences ,Scott Young ,Jodi Sievers ,Marek Ciszewski ,Klinge Pharma ,Coherus Biosciences Inc ,Securities Exchange ,Crimson Merger Subi Inc ,Glaxosmithkline ,Drug Administration ,Coheru Investor Relations Department ,Nasdaq ,Arnold Porter Kaye Scholer ,Crimson Merger Sub ,Wedbush Securities Inc ,Surface Oncology Inc ,Surface Investor Relations Department At Copies ,Novartis ,Vp Corporate Communications ,Latham Watkins ,Goodwin Procter ,Investor Relations Corporate Communications ,Coherui O ,Surface Oncology ,Chief Executive Officer ,United States Food ,Porter Kaye Scholer ,Wedbush Securities ,Daylight Time ,Biologics License Application ,Merger Sub ,Securities Act ,Securities Exchange Act ,Exchange Act ,Annual Reports ,Quarterly Reports ,Registration Statement ,Investor Relations Department ,General Meeting ,Annual Report ,Investor Relations ,Nation World ,Region ,